Otsuka’s Paradise Device Lowers Systolic Blood Pressure by 19.5 mmHg at 12 Months in Registry Study

• Recor Medical, an Otsuka Medical Devices subsidiary, announced results showing sustained blood pressure reductions with its Paradise ultrasound renal denervation system.
• Results were presented at the 2026 Transcatheter Cardiovascular Therapeutics conference, including real-world findings and four-year follow-up data.
• European and US real-world studies showed blood pressure reductions at 12 months, with favorable safety outcomes.
• Pooled RADIANCE trial results showed blood pressure reductions persisted through four years, with no new long-term safety concerns.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otsuka Holdings Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030800PRIMZONEFULLFEED9868206) on November 03, 2026, and is solely responsible for the information contained therein.